This product is a rifamycin derivative and is the first non-aminoglycoside intestinal antibiotic. It has good antibacterial activity against Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus faecalis among Gram-positive aerobic bacteria, and against Salmonella, Escherichia coli, Shigella and Yersinia enterocolitica among Gram-negative aerobic bacteria. It has high antibacterial activity against Proteus, Clostridium difficile among Gram-positive anaerobic bacteria, and Bacteroides among Gram-negative anaerobic bacteria. This product is not absorbed and maintains extremely high concentrations in the intestine, while it does not exist in other organs. It is not necessary to use intestinal antispasmodics or intestinal adsorbents when using this product. It acts quickly and can quickly relieve symptoms of diarrhea, abdominal cramps, headaches, nausea and vomiting. It does not damage hearing function, does not cause renal damage, avoids repeated infections, and intestinal mucosal inflammation tends to disappear.

This product is a derivative of rifamycin and is the first non-aminoglycoside intestinal antibiotic. It has good antibacterial activity against Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus faecalis among Gram-positive aerobic bacteria, and against Salmonella, Escherichia coli, Shigella and Yersinia enterocolitica among Gram-negative aerobic bacteria. It has high antibacterial activity against Proteus, Clostridium difficile among Gram-positive anaerobic bacteria, and Bacteroides among Gram-negative anaerobic bacteria. This product is not absorbed and maintains a very high concentration in the intestine. It acts quickly. After 2 days, diarrhea will no longer occur, and abdominal cramps, headaches, nausea and vomiting symptoms will disappear quickly. This product is superior to neomycin, streptomycin and other aminoglycoside antibiotics in the following characteristics: ① It does not damage hearing function; ② It does not cause renal damage; ③ The parasitic normal flora, especially the intestinal non-pathogenic bacteria Escherichia coli, quickly re-colonizes the intestine to avoid repeated infection; ④ Intestinal mucositis may tend to disappear.

This product is a rifamycin derivative and is the first non-aminoglycoside intestinal antibiotic. It has good antibacterial activity against Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus faecalis among Gram-positive aerobic bacteria, and against Salmonella, Escherichia coli, Shigella and Yersinia enterocolitica among Gram-negative aerobic bacteria. It has high antibacterial activity against Proteus, Clostridium difficile among Gram-positive anaerobic bacteria, and Bacteroides among Gram-negative anaerobic bacteria. This product is not absorbed and maintains extremely high concentrations in the intestine, while it does not exist in other organs. It is not necessary to use intestinal antispasmodics or intestinal adsorbents when using this product. This product is superior to neomycin, streptomycin and other aminoglycoside antibiotics in the following characteristics: ① It does not damage hearing function; ② It does not cause renal damage; ③ The parasitic normal flora, especially the intestinal non-pathogenic bacteria Escherichia coli, quickly re-colonizes the intestine to avoid repeated infection; ④ Intestinal mucositis may tend to disappear.

This product is a selective 5-HT3 receptor antagonist. Its mechanism of action may be to antagonize the 5-HT3 receptors in the peripheral vagus nerve endings and central chemoreceptor areas, thereby blocking the vomiting reflex caused by factors such as chemotherapy and surgery that promote the release of 5-HT from intestinal chromaffin cells and excite the vagus afferent nerves. This product has high selectivity and no side effects such as extrapyramidal reactions and excessive sedation.